Sirona Biochem Announces Jacques Cousteau’s Son and Grandson as Brand Ambassadors

March 27, 2014 – Sirona Biochem Corp.

VANCOUVER, BC– Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that Jean-Michel Cousteau and Fabien Cousteau (son and grandson of Jacques Cousteau) will become Brand Ambassadors for the Company. A formal Brand Ambassador launch event has been scheduled for April 8, 2014 at TFChem in Val de Reuil, France.

As Brand Ambassadors for Sirona Biochem, Jean-Michel Cousteau and Fabien Cousteau will publicize our partnership’s alliance and goals to industry experts, commercial partners and investors. Sirona Biochem will contribute its cosmetic, pharmaceutical and scientific expertise and Sirona will become a primary scientific resource for the potential commercialization of new ocean resources in collaboration with the Cousteaus. The Cousteaus and Sirona also share the goal of establishing a new accreditation for consumer packaged goods to validate technologies that are safe both for consumers and our fragile environments.

The launch event is scheduled to include a tour of the TFChem laboratory followed by a reception for attendees. Notable attendees are expected to include members of the French government, pharmaceutical and cosmetic industry leaders, and media representatives. This event is by invitation only.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Contact Information

For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064